Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the long term safety and tolerability of ALK-001
(C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of
Stargardt disease in patients between the ages of 8 and 70 years old.
Funding Source - FDA OOPD